ERBB2 and breast cancer: suggests the concept of phenotypic switching between BC molecular subtypes, as evident from the gene expression studies before, during, and after neoadjuvant therapy with lapatinib and trastuzumab in HER2+/HER2-enriched tumors of the PAMELA trial and BC cell lines (17).